PMID- 27749579
OWN - NLM
STAT- MEDLINE
DCOM- 20170209
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 40
DP  - 2016 Oct
TI  - Drug-drug interactions with imatinib: An observational study.
PG  - e5076
LID - 10.1097/MD.0000000000005076 [doi]
LID - e5076
AB  - Many patients treated with imatinib, used in cancer treatment, are using several 
      other drugs that could interact with imatinib. Our aim was to study all the 
      drug-drug interactions (DDIs) observed in patients treated with imatinib.We 
      performed 2 observational studies, between the 1st January 2012 and the 31st 
      August 2015 in the Midi-Pyrenees area (South Western France), using the French 
      health insurance reimbursement database and then the French Pharmacovigilance 
      Database (FPVD).A total of 544 patients received at least 1 reimbursement for 
      imatinib. Among them, 486 (89.3%) had at least 1 drug that could potentially 
      interact with imatinib. Paracetamol was the most frequent drug involved (77.4%). 
      Proton pump inhibitors, dexamethasone and levothyroxine, were found in >10% of 
      patients. In the FPVD, among a total of 25 reports of ADRs with imatinib recorded 
      in the Midi-Pyrenees area, 10 (40%) had potential DDIs with imatinib. Imatinib 
      was most frequently prescribed by hospital physicians and drugs interacting with 
      imatinib, by general practitioners.Our study showed that at least 40% of the 
      patients treated with imatinib were at risk of DDIs and that all prescribers must 
      be cautious with DDIs in patients treated with imatinib. During imatinib 
      treatment, we particularly recommend to limit the dose of paracetamol at 1300 mg 
      per day, to avoid the use of dexamethasone, and to double the dose of 
      levothyroxine.
FAU - Recoche, Isabelle
AU  - Recoche I
AD  - Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medecine de 
      l'Universite de Toulouse and Service de Pharmacologie Clinique, Centre 
      Midi-Pyrenees de PharmacoVigilance, de PharmacoEpidemiologie et d'Informations 
      sur le Medicament, Centre Hospitalier Universitaire Echelon Regional du Service 
      Medical de la CNAM-TS Midi-Pyrenees Laboratoire de Pharmacologie Medicale et 
      Clinique, Equipe de PharmacoEpidemiologie, Faculte de Medecine de l'Universite de 
      Toulouse and Service de Pharmacologie Clinique, Centre Hospitalier Universitaire, 
      Toulouse, France.
FAU - Rousseau, Vanessa
AU  - Rousseau V
FAU - Bourrel, Robert
AU  - Bourrel R
FAU - Lapeyre-Mestre, Maryse
AU  - Lapeyre-Mestre M
FAU - Chebane, Leila
AU  - Chebane L
FAU - Despas, Fabien
AU  - Despas F
FAU - Montastruc, Jean-Louis
AU  - Montastruc JL
FAU - Bondon-Guitton, Emmanuelle
AU  - Bondon-Guitton E
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Analgesics, Non-Narcotic)
RN  - 0 (Antineoplastic Agents)
RN  - 362O9ITL9D (Acetaminophen)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Acetaminophen/*pharmacology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics, Non-Narcotic/pharmacology
MH  - Antineoplastic Agents/pharmacology
MH  - Child
MH  - Drug Interactions
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - France/epidemiology
MH  - Humans
MH  - Imatinib Mesylate/*pharmacology
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Substance-Related Disorders
MH  - Young Adult
PMC - PMC5059082
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/10/18 06:00
MHDA- 2017/02/10 06:00
PMCR- 2016/10/07
CRDT- 2016/10/18 06:00
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/02/10 06:00 [medline]
PHST- 2016/10/18 06:00 [entrez]
PHST- 2016/10/07 00:00 [pmc-release]
AID - 00005792-201610040-00061 [pii]
AID - 10.1097/MD.0000000000005076 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Oct;95(40):e5076. doi: 10.1097/MD.0000000000005076.